Please provide your email address to receive an email when new articles are posted on . The FDA approved iDose TR for the treatment of open-angle glaucoma and ocular hypertension. Commercial launch ...

Please provide your email address to receive an email when new articles are posted on . One-fifth of patients who received ocular steroid injections were later diagnosed with glaucoma or ocular ...

The FDA approved the travoprost intracameral implant (iDose TR) for treatment of ocular hypertension and glaucoma, device developer Glaukos announced on Thursday. The implant is designed to provide ...

iDose TR is expected to be available in the first quarter of 2024. The Food and Drug Administration (FDA) has approved iDose ® TR (travoprost intracameral implant) for the reduction of intraocular ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager ™ DSLT, the ...

Between February 1994 and October 1996, 3,328 individuals were considered for the study enrollment and 1,636 individuals met the requirements for the study. Recruitment was extended from 24 months to ...

Higher polygenic risk score (PRS) was associated with an increased risk for primary open-angle glaucoma (POAG) in patients with ocular hypertension, according to a post-hoc analysis of the Ocular ...

Only about a quarter of patients with ocular hypertension lose peripheral vision, so clinicians should not recommend treatment to everyone with this condition, a long-term study suggests. The 20-year ...

In matched cohorts of more than 41,000 patients each, use of tirzepatide was linked to a significantly reduced risk of ...

USA: A large retrospective cohort study found that the dual GIP/GLP-1 receptor agonist tirzepatide was associated with a ...